Cardiovascular Drugs Practice Questions

Q: Which of the following vitamins is used to increase HDL levels?

Nicotinic acid. **Explanation:** **Nicotinic acid (Niacin/Vitamin B3)** [1] is the correct answer because it is the most potent agent currently available for increasing **HDL-C levels** (by 15–35%). It achieves this by inhibiting the hepatic uptake of Apolipoprotein A-I (ApoA-I), thereby increasing its half-life and the circulating levels of HDL. Additionally, it inhibits the enzyme *diacylglycerol acyltransferase-2* in the liver, leading to decreased triglyceride synthesis and reduced VLDL/LDL levels. **Analysis of Incorrect Options:** * **Folic acid (B9):** Primarily used for DNA synthesis and erythropoiesis. While it helps lower homocysteine levels (a cardiovascular risk factor), it has no direct effect on HDL or lipid profiles. * **Thiamine (B1):** Acts as a cofactor for carbohydrate metabolism (e.g., pyruvate dehydrogenase). Deficiency leads to Beriberi or Wernicke-Korsakoff syndrome, but it does not modulate lipids. * **Pyridoxine (B6):** Involved in amino acid metabolism and heme synthesis. Like folic acid, it reduces homocysteine but does not increase HDL. **High-Yield Clinical Pearls for NEET-PG:** * **Adverse Effect:** The most common side effect is **cutaneous flushing** and pruritus, mediated by **Prostaglandin D2**. This can be minimized by pre-treating with **Aspirin** (30 mins prior). * **Metabolic Effects:** Niacin can cause **hyperuricemia** (precipitating gout) and **hyperglycemia** (impaired glucose tolerance) [2], [3], so it should be used cautiously in diabetic patients. * **Acanthosis Nigricans:** High doses of nicotinic acid are a known pharmacological cause of this skin condition.

Q: Which among the following drugs is NOT used orally?

Lignocaine. **Explanation:** The correct answer is **Lignocaine** (Lidocaine). **1. Why Lignocaine is the correct answer:** Lignocaine is a Class IB antiarrhythmic drug that is **not administered orally** because it undergoes **extensive first-pass metabolism** in the liver (nearly 70%). If taken orally, its bioavailability is too low to reach therapeutic plasma concentrations, and its metabolites can increase the risk of central nervous system toxicity. Therefore, it is administered intravenously (for arrhythmias) or topically/locally (as an anesthetic). **2. Analysis of Incorrect Options:** * **Verapamil (Option B):** A Class IV Calcium Channel Blocker used for supraventricular tachycardia, hypertension, and angina. Although it has a significant first-pass effect, it is available in oral formulations with adjusted dosages. * **Phenytoin (Option C):** A Class IB antiarrhythmic (specifically for digoxin-induced arrhythmias) and an antiepileptic. It has good oral bioavailability and is commonly used in tablet or suspension form. * **Quinidine (Option D):** A Class IA antiarrhythmic drug. It is well-absorbed from the gastrointestinal tract and is administered orally for the maintenance of sinus rhythm in patients with atrial fibrillation/flutter. **3. High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Lignocaine is the drug of choice for **ventricular arrhythmias** occurring post-myocardial infarction (though amiodarone is now often preferred in ACLS protocols). * **Toxicity:** Lignocaine toxicity primarily affects the CNS, presenting as seizures, tremors, or blurred vision. * **Other non-oral drugs:** Remember that **Bretylium** and **Adenosine** are also antiarrhythmics that are not given orally (Adenosine has a half-life of <10 seconds and must be given as a rapid IV bolus). * **Mexiletine:** This is a Class IB analogue of lignocaine that *is* orally effective because it resists first-pass metabolism.

Q: Which of the following antihypertensive drugs can cause a "SLE-like reaction"?

Hydralazine. **Explanation:** **Hydralazine** is a direct-acting arterial vasodilator. It is classically associated with **Drug-Induced Lupus Erythematosus (DILE)**. The underlying mechanism involves the drug acting as a hapten or interfering with immune tolerance. A key pharmacological concept for NEET-PG is that hydralazine is metabolized via **N-acetylation** in the liver. **"Slow acetylators"** (individuals with a genetic deficiency in the N-acetyltransferase enzyme) are at a significantly higher risk of developing this SLE-like reaction because the drug remains in the system longer, leading to the formation of reactive metabolites. **Analysis of Incorrect Options:** * **Minoxidil:** A potent potassium channel opener used for refractory hypertension and alopecia. It causes significant fluid retention and hypertrichosis but not DILE. * **Diazoxide:** A potassium channel opener used in hypertensive emergencies and to treat insulinomas (as it inhibits insulin release). It can cause hyperglycemia but not lupus-like symptoms. * **Fenoldopam:** A selective Dopamine-1 (D1) receptor agonist used in hypertensive emergencies. It promotes natriuresis and maintains renal perfusion; it is not associated with autoimmune reactions. **High-Yield Clinical Pearls for NEET-PG:** * **DILE Markers:** Unlike systemic SLE, DILE is characterized by **Anti-Histone Antibodies** (positive in >95% of cases). Anti-dsDNA is usually negative. * **Common Culprits:** Remember the mnemonic **"SHIPP"**: **S**ulfonamides, **H**ydralazine, **I**soniazid, **P**rocainamide, and **P**henytoin. * **Clinical Presentation:** DILE typically presents with fever, arthralgia, and pleuritis, but rarely involves the CNS or kidneys (unlike idiopathic SLE). Symptoms usually resolve upon drug discontinuation.

Q: Which of the following statements is true about esmolol?

All of the above.. **Explanation:** Esmolol is a unique, ultra-short-acting **cardioselective (β1-selective)** adrenergic antagonist. It is characterized by its rapid onset and very short duration of action (half-life of approximately 9 minutes) due to its metabolism by **red blood cell esterases**. * **Option A (No ISA):** Esmolol is a pure antagonist. It lacks intrinsic sympathomimetic activity (ISA), meaning it does not partially stimulate beta-receptors. This makes it highly effective at reducing heart rate and myocardial oxygen demand. * **Option B (Cardioselective):** It primarily blocks β1 receptors located in the heart. While selectivity is lost at very high doses, at therapeutic levels, it has minimal effect on β2 receptors in the bronchi or peripheral vasculature. * **Option C (Precipitate Heart Failure):** Like all beta-blockers, esmolol is a **negative inotrope**. By reducing the force of myocardial contraction, it can acutely worsen cardiac output in patients with compensated heart failure or borderline hemodynamics, potentially precipitating acute heart failure. Since all three statements are pharmacologically accurate, **Option D** is the correct answer. **High-Yield Clinical Pearls for NEET-PG:** * **Metabolism:** It is the only beta-blocker metabolized by **plasma esterases** (not liver or kidney), making it safe in hepatic or renal failure. * **Indications:** Preferred for intraoperative tachycardia/hypertension, supraventricular arrhythmias (SVT), and hypertensive emergencies (especially aortic dissection). * **Administration:** Given only via **intravenous (IV)** route because of its rapid metabolism. * **Mnemonic:** Remember the **"B-E-A-M"** for cardioselective blockers: **B**isoprolol, **E**smolol, **A**tenolol, **M**etoprolol.

Q: Which of the following statements is true about nitric oxide?

All of the above. Nitric Oxide (NO), formerly known as Endothelium-Derived Relaxing Factor (EDRF), is a potent endogenous gas and signaling molecule crucial for vascular homeostasis. **Explanation of Options:** * **Option A:** NO is synthesized from the amino acid **L-arginine** by the enzyme **Nitric Oxide Synthase (NOS)** in the presence of oxygen and NADPH. There are three isoforms: nNOS (neuronal), eNOS (endothelial), and iNOS (inducible). * **Option B:** NO is a powerful **vasodilator**. It diffuses into vascular smooth muscle cells, activates **guanylyl cyclase**, and increases **cGMP** levels. This leads to dephosphorylation of myosin light chains and relaxation of smooth muscle across the systemic and pulmonary vasculature. * **Option C:** Inhaled NO is a standard treatment for **Persistent Pulmonary Hypertension of the Newborn (PPHN)** and adult pulmonary hypertension. Its advantage is "selective" pulmonary vasodilation without causing systemic hypotension, as it is rapidly inactivated by hemoglobin upon entering the systemic circulation. **Conclusion:** Since all statements are physiologically and clinically accurate, **Option D** is the correct answer. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** NO → ↑ cGMP → Protein Kinase G activation → Vasodilation. * **Inactivation:** NO has an extremely short half-life (seconds) and is neutralized by binding to the heme group of **hemoglobin**. * **Therapeutic use:** Inhaled NO is used in **ARDS** to improve oxygenation by reducing ventilation-perfusion (V/Q) mismatch. * **Drug Interaction:** Sildenafil (PDE-5 inhibitor) prevents the breakdown of cGMP, potentiating the effects of NO. Combined use with nitrates can lead to severe hypotension.

Q: Verapamil is contraindicated in:

Complete heart block. **Explanation:** **Verapamil** is a non-dihydropyridine Calcium Channel Blocker (CCB) with significant **negative inotropic, chronotropic, and dromotropic** effects [1]. Its primary site of action is the heart, specifically the SA and AV nodes. **1. Why Complete Heart Block is the Correct Answer:** Verapamil significantly slows conduction through the **Atrioventricular (AV) node** and increases the refractory period [2]. In a patient with complete heart block (3rd-degree AV block), the conduction between the atria and ventricles is already severed. Administering Verapamil can further suppress the junctional or ventricular escape rhythms, leading to severe bradycardia, asystole, or cardiovascular collapse [1], [3]. Therefore, it is strictly contraindicated in high-grade heart blocks and sick sinus syndrome. **2. Why Other Options are Incorrect:** * **Hypertension:** Verapamil causes peripheral vasodilation (though less than dihydropyridines like Amlodipine) and is an effective second-line antihypertensive [1]. * **Paroxysmal Supraventricular Tachycardia (PSVT):** Verapamil is actually a **drug of choice** for terminating acute episodes of PSVT (re-entrant tachycardias involving the AV node) because it slows AV conduction [4]. * **Angina Pectoris:** Verapamil is used in stable and vasospastic (Prinzmetal) angina as it reduces myocardial oxygen demand and prevents coronary vasospasm. **High-Yield Clinical Pearls for NEET-PG:** * **Avoid with Beta-blockers:** Never co-administer IV Verapamil with Beta-blockers due to the risk of additive cardiosuppression and heart block [3]. * **Wolff-Parkinson-White (WPW) Syndrome:** Verapamil is contraindicated in WPW with Atrial Fibrillation because it may enhance conduction through the accessory pathway, leading to Ventricular Fibrillation. * **Side Effect:** The most common non-cardiac side effect of Verapamil is **constipation** [1].

Q: Which class of drugs is considered a myocardial re-infarction inhibitor?

Beta blockers. **Explanation:** **Why Beta Blockers are Correct:** Beta-blockers (e.g., Metoprolol, Atenolol, Carvedilol) are the mainstay for secondary prevention post-Myocardial Infarction (MI). They act by competitively inhibiting $\beta_1$ receptors in the heart, leading to decreased heart rate, contractility, and systolic blood pressure. This significantly reduces **myocardial oxygen demand**. Furthermore, they increase diastolic perfusion time, improving coronary blood flow. By reducing "cardiac work" and preventing catecholamine-induced arrhythmias and ventricular remodeling, they have been clinically proven to reduce the risk of re-infarction and sudden cardiac death, thereby increasing long-term survival. **Why Other Options are Incorrect:** * **Nitrates:** While excellent for acute symptomatic relief of angina (preload reduction), they do not modify the disease process or reduce the incidence of re-infarction or mortality. * **Calcium Channel Blockers (CCBs):** Although they cause vasodilation, they are generally not first-line post-MI. Short-acting dihydropyridines (like Nifedipine) can actually cause reflex tachycardia, which may worsen ischemia. * **Potassium Channel Openers:** Drugs like Nicorandil are used for stable angina but lack robust clinical evidence for preventing re-infarction compared to Beta-blockers. **NEET-PG High-Yield Pearls:** * **TIMI Study:** Confirmed the benefit of early Beta-blocker administration in MI. * **Contraindications:** Avoid Beta-blockers in patients with bradycardia, high-grade AV block, severe active asthma, or cardiogenic shock. * **Cardioselective agents:** $\beta_1$ selective blockers (A-M: **A**tenolol, **B**isoprolol, **M**etoprolol) are preferred to minimize bronchospasm. * **Mortality Benefit:** Along with Beta-blockers, ACE inhibitors, Antiplatelets (Aspirin/Clopidogrel), and Statins are the four pillars that reduce mortality post-MI.

Question 1

Which drug prolongs life in a patient with chronic stable angina?

Accepted Answer

Beta Blocker

Answer

Aspirin

Answer

Calcium Channel Blocker

Answer

ACE inhibitor

Question 2

Which of the following antihypertensive agents is most likely to cause an exaggerated response to an injected catecholamine?

Accepted Answer

Guanethidine

Answer

Propranolol

Answer

Hydralazine

Answer

A thiazide diuretic

Question 3

Which of the following vitamins is used to increase HDL levels?

Accepted Answer

Nicotinic acid

Answer

Folic acid

Answer

Thiamine

Answer

Pyridoxine

Question 4

Which among the following drugs is NOT used orally?

Accepted Answer

Lignocaine

Answer

Verapamil

Answer

Phenytoin

Answer

Quinidine

Question 5

Which of the following antihypertensive drugs can cause a "SLE-like reaction"?

Accepted Answer

Hydralazine

Answer

Minoxidil

Answer

Diazoxide

Answer

Fenoldopam

Question 6

Which of the following statements is true about esmolol?

Accepted Answer

All of the above.

Answer

It has no intrinsic sympathomimetic activity.

Answer

It is a cardioselective beta-blocker.

Answer

It can precipitate heart failure.

Question 7

Which of the following statements is true about nitric oxide?

Accepted Answer

All of the above

Answer

Formed from L-Arginine by NO synthase

Answer

Causes vasodilation in all vessels

Answer

Used in pulmonary hypertension

Question 8

Verapamil is contraindicated in:

Accepted Answer

Complete heart block

Answer

Hypertension

Answer

Paroxysmal supraventricular tachycardia

Answer

Angina pectoris

Question 9

Which class of drugs is considered a myocardial re-infarction inhibitor?

Accepted Answer

Beta blockers

Answer

Nitrates

Answer

Calcium channel blockers

Answer

Potassium channel openers

Question 10

Which one of the following is the most appropriate drug to use for the patient described in parentheses?

Accepted Answer

Captopril (60-year-old woman with diabetic nephropathy)

Answer

Nitroprusside (50-year-old man with BP of 140/95)

Answer

Losartan (29-year-old pregnant woman)

Answer

Propranolol (40-year-old patient with peripheral vascular disease)

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?